AVROBIO, Inc. AVRO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

31/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

AVROBIO, Inc. (AVRO) generated $-60.08M in operating cash flow for fiscal year 2025. After capital expenditures of $208K, free cash flow was $-60.29M.

Cash conversion ratio was 0.81x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.81x suggests some earnings are non-cash items

Overall SharesGrow Score: 29/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

31/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

25/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

AVROBIO, Inc. Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$-60.08M	$-60.08M	$-59.08M	$-63.19M	$-97.21M
Capital Expenditure	$-208K	$-208K	$-156K	$-8K	$-267K
Free Cash Flow	$-60.29M	$-60.29M	$-59.24M	$-63.2M	$-97.48M